System Biosciences

System Biosciences is a private, revenue-generating biotechnology tools and services company that has established itself as a significant player in the research reagents market. Its business model centers on providing a broad portfolio of platform technologies, including exosome isolation and analysis kits, viral and non-viral gene delivery systems, CRISPR tools, and custom services like lentivirus packaging and stable cell line generation. While not a therapeutic developer itself, SBI's products are critical enablers for discovery-stage research across genetics, genomics, gene therapy, and biomarker discovery, positioning it to benefit from the growth of these fields. The company leverages its scientific expertise to commercialize novel research tools, aiming to be first-to-market with new inventions.

Portfolio of research tools and services spanning exosome isolation/analysis, viral/non-viral gene delivery systems (lentivirus, AAV, minicircles), CRISPR/Cas9 genome editing, imaging/reporter vectors, and liquid biopsy.

SBI competes in the fragmented life science research tools market against large conglomerates like Thermo Fisher Scientific and Merck KGaA, specialized public companies like Takara Bio, and numerous private startups. Its differentiation lies in its focused expertise in exosomes and gene delivery, a broad integrated portfolio, and a service-oriented, scientifically-driven customer approach.